How much is the domestic medical insurance price of lorlatinib? The latest price in 2024 announced!

Lorlatinib is a new generation of targeted therapy, a tyrosine kinase inhibitor, mainly used to treat non-small cell lung cancer (NSCLC). This drug is unique in its highly selective and potent inhibitory effect, especially in patients with mutations in the ALK (tyrosine kinase) and ROS1 (ROS proto-oncogene 1) genes.

Lorlatinib has been launched in China and is included in medical insurance. Patients can purchase it domestically, but the price is relatively high, about 10,000 to 20,000 yuan. For specific medical insurance reimbursement prices, please consult the local hospital pharmacy. There are original lorlatinib drugs and cheaper generic drugs abroad. The cheaper ones are the original drug from Turkey, which costs more than 1,000 yuan, and the original drug from Hong Kong, China, which costs about 30,000 yuan. Generic drugs are mainly generic drugs from Laos and Bangladesh. The price is about several thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.

The efficacy of lorlatinib is primarily due to its ability to block key signaling pathways in the growth and spread of cancer cells. As a member of the ALK inhibitors, lorlatinib provides a new treatment option for NSCLC patients carrying ALK mutations, especially those who have developed resistance to other treatments.

The drug has shown significant efficacy in clinical trials, especially in first-line treatment. CROWNThe results of the study showed that patients with ALKpositive NSCLC who used lorlatinib achieved significant advantages in progression-free survival (PFS), confirming the important role of this drug in improving patient survival and controlling the disease.

Another characteristic of lorlatinib is its ability to cross the blood-brain barrier, thereby also showing excellent results in the treatment ofNSCLC patients with brain metastases. This offers new therapeutic hope for many patients, especially those for whom brain metastases are a major challenge.